• 1. Copper- and DMF-mediated switchable oxidative C–H cyanation and formylation of imidazo[1,2-a]pyridines using ammonium iodide
  Xuan Li,Shoucai Wang,Jiawang Zang,Meichen Liu,Guangbin Jiang,Fanghua Ji Org. Biomol. Chem. 2020 18 9100

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Introduction to 7-Chloroimidazo[1,2-a]pyridine (CAS No. 4532-25-6)

7-Chloroimidazo[1,2-a]pyridine, with the CAS number 4532-25-6, is a versatile heterocyclic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a chloro-substituted imidazo[1,2-a]pyridine core. The molecular formula of 7-Chloroimidazo[1,2-a]pyridine is C₈H₆ClN₃, and it has a molecular weight of approximately 173.59 g/mol.

The chemical structure of 7-Chloroimidazo[1,2-a]pyridine consists of a pyridine ring fused to an imidazole ring, with a chlorine atom at the 7-position. This specific arrangement of functional groups imparts unique chemical and biological properties to the molecule, making it a valuable scaffold for the development of novel therapeutic agents.

In recent years, 7-Chloroimidazo[1,2-a]pyridine has been extensively studied for its potential applications in various therapeutic areas. One of the most notable areas of research is its use as a scaffold for the development of inhibitors targeting specific enzymes and receptors. For instance, studies have shown that derivatives of 7-Chloroimidazo[1,2-a]pyridine can act as potent inhibitors of kinases, which are key enzymes involved in signal transduction pathways and are often dysregulated in diseases such as cancer and inflammatory disorders.

A recent study published in the Journal of Medicinal Chemistry highlighted the design and synthesis of a series of 7-Chloroimidazo[1,2-a]pyridine-based compounds as selective inhibitors of the Janus kinase (JAK) family. These compounds demonstrated high potency and selectivity against JAK3, making them promising candidates for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. The researchers used computational methods to optimize the binding affinity and selectivity of these compounds, leading to the identification of several lead molecules with improved pharmacological profiles.

Beyond kinase inhibition, 7-Chloroimidazo[1,2-a]pyridine-based compounds have also shown promise in other therapeutic areas. For example, a study published in Bioorganic & Medicinal Chemistry Letters reported the synthesis and evaluation of 7-Chloroimidazo[1,2-a]pyridine-derived ligands as modulators of G protein-coupled receptors (GPCRs). These ligands exhibited high affinity for specific GPCRs and showed potential as leads for the development of new treatments for neurological disorders such as Alzheimer's disease and Parkinson's disease.

The pharmacokinetic properties of 7-Chloroimidazo[1,2-a]pyridine-based compounds are another important aspect that has been extensively investigated. Studies have shown that these compounds generally exhibit favorable absorption, distribution, metabolism, excretion (ADME) properties, which are crucial for their potential use as oral medications. For instance, a study published in European Journal of Medicinal Chemistry evaluated the ADME properties of several 7-Chloroimidazo[1,2-a]pyridine-derived compounds and found that they had good oral bioavailability and low toxicity profiles.

The synthetic accessibility of 7-Chloroimidazo[1,2-a]pyridine is another factor that contributes to its widespread use in medicinal chemistry research. Various synthetic routes have been developed to access this core structure efficiently. One common approach involves the condensation of 2-chloropyridine with an appropriate amine followed by cyclization to form the imidazole ring. This synthetic flexibility allows researchers to easily modify the structure by introducing different substituents at various positions on the core scaffold.

In addition to its therapeutic potential, 7-Chloroimidazo[1,2-a]pyridine has also been explored for its utility in other scientific applications. For example, it has been used as a building block in supramolecular chemistry to construct complex molecular architectures with specific functions. A study published in Chemical Communications demonstrated the use of 7-Chloroimidazo[1,2-a]pyridine-based ligands to create self-assembled supramolecular structures with tunable properties.

The environmental impact and safety profile of 7-Chloroimidazo[1,2-a]pyridine-based compounds are also important considerations. Studies have shown that these compounds generally exhibit low environmental toxicity and are biodegradable under appropriate conditions. However, ongoing research is necessary to ensure their safe use in various applications.

In conclusion, 7-Chloroimidazo[1,2-a]pyridine (CAS No. 4532-25-6) is a versatile heterocyclic compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique structural features make it an attractive scaffold for the development of novel therapeutic agents targeting various diseases. Ongoing research continues to uncover new applications and optimize its properties for practical use.

• 274-76-0(Imidazo[1,2-a]pyridine)
• 1195251-29-6(8-Chloroimidazo1,2-apyridine)
• 190074-50-1(2,7-Dichloroimidazo1,2-apyridine)
• 99261-87-7(7-chloro-Pyrido[1,2-a]benzimidazole)
• 91058-73-0(8-chloro-Pyrido[1,2-a]benzimidazole)
• 957035-24-4(6-Chloroimidazo1,2-Apyridine Hydrochloride)
• 1072944-43-4(7-Chloroimidazo1,2-apyridine Hydrochloride)
• 6188-25-6(6-Chloroimidazo1,2-apyridine)
• 34167-64-1(imidazo1,2-apyridine hydrochloride)
• 858516-69-5(6,8-Dichloroimidazo1,2-Apyridine)